Library — CHDR

Search

Filter

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP

The Lancet. Respiratory medicine, 2018 Aug; 1(9):714-27

View publication
Sample Aging Profoundly Reduces Monocyte Responses in Human Whole Blood Cultures.

Grievink HW, Moerland M

Journal of immunology research, 2018 Aug

View publication
Complement Activation in Inflammatory Skin Diseases.

Giang J, Seelen MAJ, van Doorn MBA, Rissmann R, Prens EP, Damman J

Frontiers in immunology, 2018 Jul

View publication
Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.

van der Kolk T, Assil S, Rijneveld R, Klaassen ES, Feiss G, Florencia E, Prens EP, Burggraaf J, Moerland M, Rissmann R, van Doorn MBA

Clinical and translational science, 2018 Jul

View publication
Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy?

Veen C, Jacobs G, Philippens I, Vermetten E

Current topics in behavioral neurosciences, 2018 Jun

View publication
Futility of current urine salbutamol doping control.

Heuberger JAAC, van Dijkman SC, Cohen AF

British journal of clinical pharmacology, 2018 May

View publication
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1.

van Gerven J, Bonelli M

British journal of clinical pharmacology, 2018 May

View publication
The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer

van Meir H, du Burck IJ, de Kam ML, Welters MJP, van der Burg SH, Trimbos JBMZ, de Kroon CD, van Poelgeest MIE.

2018 May

View publication
MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.

Reijers JAA, Kallend DG, Malone KE, Jukema JW, Wijngaard PLJ, Burggraaf J, Moerland M

Cardiovascular drugs and therapy, 2018 May; 31(4):381-389

View publication

«
1
2
3
4
5
6
7
8
...
58
59
»